The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Commentary|Articles|October 30, 2025
ESMO 2025 GI Cancer Data Highlight Emerging Precision Strategies and Treatment Avenues for Rare Cancers
Author(s)Ashling Wahner
Fact checked by: Jax DiEugenio
Revisit the most intriguing GI cancer data from the 2025 ESMO Congress.
Advertisement
Advertisement
The
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.
Paul E. Oberstein, MD, discusses data for an autogene cevumeran–based regimen in pancreatic ductal adenocarcinoma.
The FDA has issued a CRL to the NDA seeking the approval of the investigational agent 177Lu-edotreotide for the treatment of patients with GEP-NETs.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement